MAIA Biotechnology Inc (MAIA)
3.36
+0.05
(+1.51%)
USD |
NYAM |
May 07, 16:00
3.32
-0.04
(-1.19%)
After-Hours: 20:00
MAIA Biotechnology Enterprise Value: 62.00M for May 7, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 07, 2024 | 62.00M |
May 06, 2024 | 60.97M |
May 03, 2024 | 60.36M |
May 02, 2024 | 57.68M |
May 01, 2024 | 52.95M |
April 30, 2024 | 53.15M |
April 29, 2024 | 58.92M |
April 26, 2024 | 53.36M |
April 25, 2024 | 48.01M |
April 24, 2024 | 48.21M |
April 23, 2024 | 43.48M |
April 22, 2024 | 39.36M |
April 19, 2024 | 37.10M |
April 18, 2024 | 33.19M |
April 17, 2024 | 33.60M |
April 16, 2024 | 35.25M |
April 15, 2024 | 34.84M |
April 12, 2024 | 38.23M |
April 11, 2024 | 42.86M |
April 10, 2024 | 43.48M |
April 09, 2024 | 45.74M |
April 08, 2024 | 44.10M |
April 05, 2024 | 41.22M |
April 04, 2024 | 38.13M |
April 03, 2024 | 40.60M |
Date | Value |
---|---|
April 02, 2024 | 41.22M |
April 01, 2024 | 43.89M |
March 28, 2024 | 38.13M |
March 27, 2024 | 42.46M |
March 26, 2024 | 41.66M |
March 25, 2024 | 43.86M |
March 22, 2024 | 35.06M |
March 21, 2024 | 31.65M |
March 20, 2024 | 25.00M |
March 19, 2024 | 25.77M |
March 18, 2024 | 22.07M |
March 15, 2024 | 19.93M |
March 14, 2024 | 18.37M |
March 13, 2024 | 15.61M |
March 12, 2024 | 15.10M |
March 11, 2024 | 14.90M |
March 08, 2024 | 15.44M |
March 07, 2024 | 16.63M |
March 06, 2024 | 17.82M |
March 05, 2024 | 17.99M |
March 04, 2024 | 17.48M |
March 01, 2024 | 16.55M |
February 29, 2024 | 15.10M |
February 28, 2024 | 16.29M |
February 27, 2024 | 15.95M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
7.975M
Minimum
Dec 12 2023
75.94M
Maximum
Aug 01 2022
26.05M
Average
24.17M
Median
Oct 13 2023
Enterprise Value Benchmarks
Cyclacel Pharmaceuticals Inc | -0.5964M |
Avid Bioservices Inc | 666.80M |
Oragenics Inc | 4.426M |
NeuBase Therapeutics Inc | -11.08M |
Viking Therapeutics Inc | 7.813B |
Enterprise Value Related Metrics
Net Income (Quarterly) | -6.257M |
Total Expenses (Quarterly) | 6.351M |
EPS Diluted (Quarterly) | -0.41 |
Earnings Yield | -44.64% |